1321 related articles for article (PubMed ID: 7809506)
41. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
42. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
43. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
44. A novel WT1 gene mutation associated with wilms' tumor and congenital male genitourinary malformation.
Sakamoto J; Takata A; Fukuzawa R; Kikuchi H; Sugiyama M; Kanamori Y; Hashizume K; Hata JI
Pediatr Res; 2001 Sep; 50(3):337-44. PubMed ID: 11518820
[TBL] [Abstract][Full Text] [Related]
45. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
46. Lack of linkage of familial Wilms' tumour to chromosomal band 11p13.
Huff V; Compton DA; Chao LY; Strong LC; Geiser CF; Saunders GF
Nature; 1988 Nov; 336(6197):377-8. PubMed ID: 2848200
[TBL] [Abstract][Full Text] [Related]
47. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours.
Schulz S; Becker KF; Braungart E; Reichmuth C; Klamt B; Becker I; Atkinson M; Gessler M; Höfler H
J Pathol; 2000 Jun; 191(2):162-9. PubMed ID: 10861576
[TBL] [Abstract][Full Text] [Related]
48. Nonlinkage of 16q markers to familial predisposition to Wilms' tumor.
Huff V; Reeve AE; Leppert M; Strong LC; Douglass EC; Geiser CF; Li FP; Meadows A; Callen DF; Lenoir G
Cancer Res; 1992 Nov; 52(21):6117-20. PubMed ID: 1356625
[TBL] [Abstract][Full Text] [Related]
49. Blastemal cells of nephroblastomatosis complex share an onco-developmental antigen with embryonic kidney and Wilms' tumor. An immunohistochemical study on polysialic acid distribution.
Roth J; Blaha I; Bitter-Suermann D; Heitz PU
Am J Pathol; 1988 Dec; 133(3):596-608. PubMed ID: 2849302
[TBL] [Abstract][Full Text] [Related]
50. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
Morrison DJ; English MA; Licht JD
Cancer Res; 2005 Sep; 65(18):8174-82. PubMed ID: 16166292
[TBL] [Abstract][Full Text] [Related]
51. Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11.
Mannens M; Devilee P; Bliek J; Mandjes I; de Kraker J; Heyting C; Slater RM; Westerveld A
Cancer Res; 1990 Jun; 50(11):3279-83. PubMed ID: 2159377
[TBL] [Abstract][Full Text] [Related]
52. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
[TBL] [Abstract][Full Text] [Related]
53. Loss of heterozygosity at 7p in Wilms' tumour development.
Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
[TBL] [Abstract][Full Text] [Related]
54. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
55. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
56. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor.
Ohshima J; Haruta M; Arai Y; Kasai F; Fujiwara Y; Ariga T; Okita H; Fukuzawa M; Hata J; Horie H; Kaneko Y
Genes Chromosomes Cancer; 2009 Dec; 48(12):1037-50. PubMed ID: 19760604
[TBL] [Abstract][Full Text] [Related]
57. Restoration of p53 function in anaplastic Wilms' tumor.
Delatte SJ; Hazen-Martin DJ; Re GG; Kelly JR; Sutphin A; Tagge EP
J Pediatr Surg; 2001 Jan; 36(1):43-50. PubMed ID: 11150436
[TBL] [Abstract][Full Text] [Related]
58. Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney.
Dekel B; Metsuyanim S; Schmidt-Ott KM; Fridman E; Jacob-Hirsch J; Simon A; Pinthus J; Mor Y; Barasch J; Amariglio N; Reisner Y; Kaminski N; Rechavi G
Cancer Res; 2006 Jun; 66(12):6040-9. PubMed ID: 16778176
[TBL] [Abstract][Full Text] [Related]
59. Molecular biology of Wilms' tumor.
Koo HP; Hensle TW
Urol Clin North Am; 1993 May; 20(2):323-31. PubMed ID: 8388135
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of p53 expression in Wilms' tumor in children.
Skotnicka-Klonowicz G; Kobos J; Łoś E; Trejster E; Szymik-Kontorowicz S; Daszkiewicz P
Med Sci Monit; 2001; 7(6):1224-9. PubMed ID: 11687734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]